Brenntag SE BNR.DE
Composite 52/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 22/100 — a strong mark against it.
Momentum ranks 74/100 — a moderate point in its favour. Income ranks 73/100 — a moderate point in its favour. Valuation ranks 62/100 — a slight point in its favour.
Growth ranks 22/100 — a strong mark against it. Quality ranks 42/100 — a slight mark against it.
What the company does Brenntag SE is a global chemical and ingredient distributor serving nutrition, pharma, beauty, water treatment, and industrial markets. It offers logistics, blending, regulatory support, and digital solutions across 74 countries.
Key financials Gross margin 25.5%, operating margin 4.9%, net margin 1.5%. ROE 5.0%, ROA 3.8%, ROCE 6.9%. Revenue fell 10.1% and EPS 26.9% in the latest period. Debt/Equity 0.75, net debt/EBITDA 2.86, interest coverage 3.77.
Stock health Sideravia scores: Quality 33.5, Growth 21.0, Strength 58.9, Valuation 62.1, Momentum 61.5, Income 50.8. Piotroski F-Score 5/9, Altman Z 2.95. Current ratio 1.74, RSI(14) 70.60.
Price vs fair value Brenntag trades at a PREMIUM of 30.40% versus our fair-value estimate and at a PREMIUM of 8.28% versus the 12-month analyst target. - Forward P/E 10.86 vs trailing 37.51 (Valuation 62.1 percentile) - PEG 0.04 signals extreme earnings-based value (Valuation 62.1 percentile) - Net margin 1.5% and ROE 5.0% lag peers (Quality 33.5 percentile) - Revenue -10.1% and EPS -26.9% reflect cyclical headwinds (Growth 21.0 percentile)
Looking forward Analysts (14.0) set a 12-month target of 56.57, implying 8.28% upside from the current price. Momentum remains elevated with 12-month gains of 15.09% despite a pullback from the 52-week high.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.